Guardant360 CDx Test Approved for Early, 'Serial' Use in Breast Cancer

Guardant360 CDx Test Approved for Early, 'Serial' Use in Breast Cancer

The Guardant360 CDx liquid biopsy test has been FDA approved as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in certain advanced patients. This is the first test Approved to manage treatment before testing tumor size.

Guardant360 CDx Approved as Companion Diagnostic for AstraZeneca’s Etcamah in ESR1-Mutated Breast Cancer

As reported on Fierce BioTech, Guardant Health has secured U.S. Food and Drug Administration approval for its Guardant360 CDx liquid biopsy test as the companion diagnostic for AstraZeneca’s newly approved breast cancer therapy, Etcamah. The authorization follows the FDA’s Sept. 4 approval of Etcamah for use alongside a CDK4/6 inhibitor in patients with hormone receptor-positive, […]